Audit of Sex and Gender Medicine Topics in Preclinical School of Medicine Curriculum.

INTRODUCTION: The importance of the inclusion of sex and gender medicine (SGM) in medical education has been recognized formally by both the American Association of Medical Colleges and the Department of Health and Human Services since 1995. Yet, few medical schools, including the Medical College of Wisconsin, have a standard SGM curriculum. This work mapped the SGM health topics taught in the Medical College of Wisconsin preclinical curriculum. METHODS: Seven medical students audited 16 basic science preclinical courses in 2020-2021. SGM characterizations, including epidemiology, diagnosis, presentation, treatment, prognosis, pharmacology, and disparity, were captured by an online survey tool. Comparisons were made to 38 high-yield topics presented in the textbook "How Sex and Gender Impact Clinical Practice: An Evidence-Based Guide to Patient Care." RESULTS: Of the 604 preclinical sessions audited, 54% contained some SGM content. Epidemiology was the most common characterization (23% of total). Thirty-four of the 38 high-yield clinical SGM topics received mention in the basic science sessions. Breast cancer, stroke, osteoporosis, sex and gender considerations in therapeutic response, and systemic lupus erythematosus had the most frequent SGM-specific coverage (representation in at least 4 of the 16 preclinical courses). CONCLUSIONS: Utilizing a medical student cohort to thoroughly audit courses was an effective way to document that Medical College of Wisconsin preclinical curriculum introduces many clinically relevant SGM topics. However, the audit also discovered varying levels of detail among the high-yield topics with concern that students may not be adequately prepared to treat all patients. These results establish the groundwork for a more formalized and integrated approach to include SGM in preclinical curriculum.

Accelerated aging in bipolar disorder: A comprehensive review of molecular findings and their clinical implications.

Bipolar disorder (BD) has been associated with clinical signs of accelerated aging, which potentially underlies its association with several age-related medical conditions, such as hypertension, metabolic imbalances, dementia, and cancer. This paper aims to comprehensively review evidence of biological aging in BD and explore findings and controversies related to common biological clocks in patients, including telomere length, DNA methylation, mitochondrial DNA copy number, inflammation, and oxidative stress. Our results suggest a complex interplay between biological markers and a potential key role of environmental factors, such as childhood trauma and psychological stress, in determining premature aging in patients. Moreover, given its multifactorial nature, our summary evidences the need for further studies incorporating clinical evidence with biomarkers of accelerated aging in BD. Results of this review strongly suggest BD as an accelerated aging disease seen in both clinical and molecular aspects. Understanding the pathophysiology of aging in BD may ultimately lead to identification of pathways that can be targeted for prevention of premature aging in patients and early onset of aging-related conditions.

The anti-aging effects of lithium in lymphoblastoid cell lines from patients with bipolar disorder and controls.

Bipolar disorder (BD) has been previously associated with accelerated aging, and recent investigations have started to explore the potential anti-aging effects of BD treatments. Lithium, the most commonly used mood stabilizer, has been suggested to impact telomere length in specific populations, although its effects on other aging biomarkers, such as epigenetic aging, have never been investigated. We assessed the in vitro effects of lithium on telomere length and epigenetic aging in lymphoblastoid cell lines (LCLs) from 14 patients with BD and 14 controls, all matched for age, sex, and ethnicity. Our results showed that telomere length significantly correlated with chronological age in LCLs in both groups and that BD patients have shorter telomere lengths compared to controls at baseline (vehicle treatment), confirming previous in vivo findings. Moreover, lithium treatment significantly increased telomere length in LCLs from patients, but not in controls. On the other hand, epigenetic age did not correlate with chronological age and was not shown to differ between patients and controls. In addition, lithium did not induce any changes in epigenetic age in cells from either patients or controls. Overall, our results support previous reports of an anti-aging effect of lithium based on its modulation of telomere length and suggest a different lithium effect in cells from patients and controls. Finally, we also discuss the limitations of using transformed LCLs for the study of DNA methylation mechanisms.